3D Medicines (Sichuan) Co., Ltd.
Quick facts
Phase 3 pipeline
- Gemcitabine & oxaliplatin · Oncology
Gemcitabine and oxaliplatin are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, with gemcitabine acting as a nucleoside analog and oxaliplatin forming platinum-DNA crosslinks. - KN035 plus Gemcitabine & oxaliplatin · Oncology
KN035 is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with gemcitabine and oxaliplatin chemotherapy.
Phase 2 pipeline
- Envafolimab plus Gemcitabine&Cisplatin · Oncology
Envafolimab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell activation and anti-tumor immune responses. - KN035
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: